⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ESPR News
Esperion Therapeutics, Inc.
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Esperion Therapeutics, Inc. (NASDAQ: ESPR)
globenewswire.com
ESPR
Shareholder Alert: Ademi LLP investigates whether Esperion Therapeutics, Inc. is obtaining a Fair Price for Public Shareholders
prnewswire.com
ESPR
ESPR Stock Alert: Halper Sadeh LLC is Investigating Whether Esperion Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders
businesswire.com
ESPR
Esperion to Report First Quarter 2026 Financial Results on May 7
globenewswire.com
ESPR
Espresa Launches Specialty Care Accounts to Give Employers Predictable Control Over Rising Costs of Popular Drugs Such as GLP-1s
accessnewswire.com
ESPR
Form 8-K
sec.gov
ESPR
Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics
globenewswire.com
ESPR
Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)
globenewswire.com
ESPR
Esperion to Participate in 25th Annual Needham Virtual Healthcare Conference
globenewswire.com
ESPR
Esperion Showcases New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) at the American College of Cardiology’s Annual Scientific Session 2026
globenewswire.com
ESPR